Drugs / AZD9750
last change Jan 2026 re-read 9 days ago

AZD9750

Developed for
prostate cancer
Investigated by
AstraZeneca

Trials 1

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT07336446 Jan → Nov 2026 expected prostate cancer AstraZeneca Active not recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as AZD9750 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07336446 ↗